In re Aggrenox Antitrust Litigation

Case Number:  3:14-cv-02516 (SRU)
Court:  District of Connecticut
Judge:  Stefan R. Underhill
Status:  Settled

Garwin Gerstein & Fisher LLP served as lead counsel on behalf of a class of direct purchasers.  A $146 million settlement was reached in 2017.

Direct Purchaser Plaintiffs asserted that Boehringer Ingelheim, Teva, Barr, and Duramed violated antitrust laws by engaging in an unlawful scheme to delay or block the market entry of less expensive, generic versions of the prescription drug Aggrenox (extended release aspirin-dipyridamole).  The Direct Purchaser Class Plaintiffs allege that Boehringer entered into several unlawful, non-competition agreements, or horizontal market allocation agreements, with its prospective generic competitor, Barr, whereby Boehringer agreed to pay Barr, in exchange for agreements by Barr to delay selling its generic version of Aggrenox.  After the challenged agreements were entered into, Barr was acquired by Teva.

Click document titles to open them.

  1. Motion for Preliminary Approval of Settlement
  2. Class & Settlement Notice
  3. Order Granting Preliminary Approval of Settlement & Certifying Class
  4. Motion for Attorneys Fees, Costs, and Incentive Awards
  5. Motion for Final Approval of Settlement
  6. Final Judgment and Order of Dismissal
© Garwin Gerstein & Fisher LLP 2018  
88 Pine Street 10th Floor,
New York, NY 10005
Attorney Advertising   Disclaimer